New Guidelines Question Long-Term Beta Blocker Use After Heart Attacks for Stable Patients

For decades, beta blockers have been a standard long-term treatment following heart attacks to reduce the risk of further cardiac events. However, recent research and updated 2023 guidelines from the American Heart Association and the American College of Cardiology challenge the necessity of prolonged beta blocker therapy for all patients, especially those with stable heart function and no recent heart attacks.

Beta blockers lower blood pressure and heart rate by blocking adrenaline receptors, easing the heart's workload. A recent South Korean study published in the New England Journal of Medicine examined 2,540 stable patients at least one year post-heart attack with preserved left ventricular function. Participants were randomized to either discontinue beta blockers or continue treatment, with follow-up over three years assessing mortality, recurrent heart attacks, and heart failure hospitalizations. The study found no significant difference in outcomes between the groups, suggesting that stopping beta blockers after one year may be safe for selected patients.

Prof. Ofer Havakuk of Ichilov Medical Center explained that advances in cardiac care, such as rapid artery-opening procedures and improved medications, have reduced the relative benefit of long-term beta blocker use. He emphasized that patients with impaired left ventricular function or arrhythmias should continue beta blockers, while those with normal heart function might consider discontinuation under medical supervision. Side effects like fatigue and sexual dysfunction may also warrant stopping treatment.

The guidelines recommend reassessing beta blocker therapy about one year after a heart attack and tailoring decisions to individual clinical situations. Sudden cessation of beta blockers should be avoided, especially at high doses, to prevent adverse effects. Although the South Korean study's findings are promising, further research in diverse populations is needed before widespread changes in practice.

In summary, beta blockers remain crucial for certain patients post-heart attack, but their universal long-term use is being reconsidered in light of new evidence and improved cardiac treatments.